People diagnosed with a life-threatening cardiac condition have been given new hope, thanks to a ground-breaking new drug that protects the heart developed by researchers from UCL and the Royal Free Hospital.
Jan 11, 2024
0
63
Researchers from IBB-UAB have developed a second-generation molecule that significantly improves the stabilization and inhibition of the aggregation of proteins involved in Transthyretin Amyloidosis (ATTR), a group of minority ...
Oct 18, 2023
0
35
Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Aug 28, 2023
1
34
A new multi-center study led by doctors at Boston Medical Center and Columbia University found that having a genetic variant in the prealbumin gene alone is not sufficient for diagnosis of transthyretin amyloid cardiomyopathy ...
Jul 28, 2023
0
41
A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly reduced circulating transthyretin (TTR) protein levels in patients with ATTR amyloid cardiomyopathy, a progressive and fatal ...
Nov 7, 2022
0
32
Columbia researchers have found a link between a common back ailment and a type of heart failure, suggesting that screening patients with lumbar spinal stenosis could identify those at risk of the heart disease and prevent ...
Aug 31, 2022
0
1450
